C4 Therapeutics, Inc.
CCCC
$4.24
$0.163.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.64M | -25.13M | -20.49M | -32.17M | -26.02M |
| Total Depreciation and Amortization | 292.00K | 404.00K | 428.00K | 460.00K | 615.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.32M | 3.05M | 4.59M | 16.53M | 6.10M |
| Change in Net Operating Assets | 17.45M | -8.27M | -6.68M | -16.03M | 7.25M |
| Cash from Operations | -1.57M | -29.94M | -22.15M | -31.21M | -12.06M |
| Capital Expenditure | -37.00K | -64.00K | -11.00K | -411.00K | -185.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.78M | 16.22M | -80.72M | 4.50M | 39.11M |
| Cash from Investing | -14.82M | 16.15M | -80.73M | 4.09M | 38.92M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 33.73M | 606.00K | 118.69M | 7.63M | -- |
| Repurchase of Common Stock | 0.00 | -200.00K | -14.00K | -24.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 56.00K | 1.00K | 164.00K | 0.00 |
| Cash from Financing | 33.73M | 462.00K | 118.67M | 7.77M | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.34M | -13.33M | 15.79M | -19.35M | 26.86M |